Rank #1941FHTX

Foghorn Therapeutics Inc.

$5.83

3.00% (Daily)

Market Cap

$341.53M

Revenue

$24.52M

Rank by MCap

#1941

Sector

Healthcare

Industry

Biotechnology

CEO

Mr. Adrian H. B. Gottschalk

Headquarters

Cambridge, MA

Employees

112

About Foghorn Therapeutics Inc.

Foghorn Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of medicines targeting genetically determined dependencies within the chromatin regulatory system in the United States. The company uses its proprietary Gene Traffic Control platform to identify, validate, and potentially drug targets within the system. It is also developing therapies for mutant cancers, such as androgen receptor, positive prostate cancer, bladder cancer, Non-Small ...